Article
Short Communication: Nucleoside Reverse Transcriptase Inhibitors with Reduced Predicted Activity Do Not Impair Second-Line Therapy with Lopinavir/Ritonavir or Darunavir/Ritonavir.
AIDS research and human retroviruses - 1 Jun 2018
Villabona-Arenas Christian Julian, Eymard-Duvernay Sabrina, Aghokeng Avelin, Guichet Emilande, Toure-Kane Coumba, Bado Guillaume, Koulla-Shiro Sinata, Delaporte Eric, Ciaffi Laura, Peeters Martine
Abstract excerpt
Second-line therapy randomized trials with lopinavir/ritonavir question the value of resistance testing to guide nucleoside reverse transcriptase inhibitor (NRTI) selection. In this study, we investigated the association between baseline drug resistance and treatment outcome after 104 weeks of second-line therapy with NRTIs and either darunavir/ritonavir or lopinavir/ritonavir in West-central Africa. We did an...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.